- Home
- HRMY vs MNR Comparison
HRMY vs MNR Comparison
Compare HRMY & MNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- MNR
- Stock Information
- Founded
- HRMY 2017
- MNR 2017
- Country
- HRMY United States
- MNR United States
- Employees
- HRMY 268
- MNR N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- MNR
- Sector
- HRMY Health Care
- MNR
- Exchange
- HRMY Nasdaq
- MNR Nasdaq
- Market Cap
- HRMY 1.8B
- MNR 1.7B
- IPO Year
- HRMY 2020
- MNR 2023
- Fundamental
- Price
- HRMY $32.16
- MNR $14.75
- Analyst Decision
- HRMY Strong Buy
- MNR Strong Buy
- Analyst Count
- HRMY 9
- MNR 3
- Target Price
- HRMY $54.22
- MNR $24.00
- AVG Volume (30 Days)
- HRMY 620.8K
- MNR 455.5K
- Earning Date
- HRMY 08-05-2025
- MNR 08-12-2025
- Dividend Yield
- HRMY N/A
- MNR 18.64%
- EPS Growth
- HRMY 13.13
- MNR 705.75
- EPS
- HRMY 2.62
- MNR 1.56
- Revenue
- HRMY $744,852,000.00
- MNR $941,846,000.00
- Revenue This Year
- HRMY $20.10
- MNR $4.44
- Revenue Next Year
- HRMY $18.01
- MNR $2.27
- P/E Ratio
- HRMY $12.27
- MNR $9.43
- Revenue Growth
- HRMY 20.62
- MNR 22.14
- 52 Week Low
- HRMY $26.47
- MNR $12.40
- 52 Week High
- HRMY $41.61
- MNR $20.94
- Technical
- Relative Strength Index (RSI)
- HRMY 43.25
- MNR 58.69
- Support Level
- HRMY $31.70
- MNR $14.26
- Resistance Level
- HRMY $33.69
- MNR $14.81
- Average True Range (ATR)
- HRMY 0.89
- MNR 0.41
- MACD
- HRMY -0.10
- MNR -0.01
- Stochastic Oscillator
- HRMY 37.30
- MNR 36.80
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.